PRL and breast cancer: Though the Stat1-knockout, BLG-Cre; Kras(G12V), and NRL-PRL models develop HR+ mammary tumors that are sensitive to hormonal perturbations such as ovariectomy and fulvestrant treatment [55, 56], they all are hindered in their utilization potential by their driver mutations.